OI Therapy Raised BMD, Not Fracture Benefit - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

OI Therapy Raised BMD, Not Fracture Benefit

Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.

  • By

  • Andrea Surnit

  • June 5, 2026

  • 7 min

Share

Original Source(s)

OI Therapy Raised BMD, Not Fracture Benefit

  • by Andrea Surnit

  • June 5, 2026

Related Content

Blood urea nitrogen to albumin ratio and 1-year mortality after hip fracture surgery in older adults: a retrospective cohort study

Clinical and radiographic factors associated with surgical approach selection in total hip arthroplasty: a preliminary machine learning analysis

Comparison of pediatric proximal femoral locking plates and dynamic hip screws in the fixation of pediatric intertrochanteric fractures, a biomechanical study